Risk reduction in HCM: when the gradient is gone, do we still need an ICD?
Speaker Angelos Rigopoulos
Event : ESC Congress 2018
- Topic : arrhythmias and device therapy
- Sub-topic : Hypertrophic Cardiomyopathy
- Session type : Advances in Science
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.